Page 1

¿ CareDx Your Partner in Transplant Care CareDx Reports Third Quarter 2021 Results Increases Full Year Revenue Guidance Exhibit 99.1 SOUTH SAN FRANCISCO , Calif . , October 28 , 2021 ( GLOBE NEWSWIRE ) -- CareDx , Inc. ( Nasdaq : CDNA ) , a leading precision medicine company focused on the discovery , development , and commercialization of clinically differentiated , high - value healthcare solutions for transplant patients and caregivers , today reported financial results for the third quarter ended September 30 , 2021 . Recent Highlights : • • • • Achieved record revenue of $ 75.6 million for the three months ended September 30 , 2021 , increasing 42 % year - over - year Grew testing services volume 86 % year - over - year , with approximately 40,000 AlloSure and AlloMap patient results provided in the quarter - highlighted by an approximately 90 % attach rate for HeartCare Announced publication of KidneyCare validation study in Kidney360 – Multicenter study validating AlloMap and demonstrating the complementary value with AlloSure for detecting rejection Received first commercial AlloSure Lung coverage , followed by commercial launch of AlloSure Lung , the first dd - cfDNA test available for lung transplant patients , in October " I'm pleased with our strong performance in the third quarter , driven by 86 % volume growth in testing services , " said Reg Seeto , President and Chief Executive Officer of CareDx . " We made significant progress toward our goal of OrganCare multi - modality , while continuing our pan- organ leadership in being the first with dd - cfDNA in Heart , Kidney and now Lung . We remain 100 % committed to patients , and to transforming the transplant patient journey through innovation . " Third Quarter 2021 Financial Results Revenue for the three months ended September 30 , 2021 was $ 75.6 million , an increase of 42 % compared with $ 53.4 million in the third quarter of 2020. Testing services revenue for the third quarter was $ 66.5 million , compared with $ 45.5 million in the same period of 2020. Product revenue in the three months ended September 30 , 2021 was $ 6.5 million , compared to $ 5.4 million in the same period of 2020. Digital and other revenue for the third quarter of 2021 was $ 2.6 million . For the third quarter of 2021 , net loss was $ 11.9 million compared to a net loss of $ 2.8 million in the same period of 2020. Basic and diluted net loss per share was $ 0.23 in the third quarter of 2021 , compared to basic and diluted net loss per share of $ 0.06 in the third quarter of 2020 . Non - GAAP net income was $ 4.0 million in the third quarter of 2021 compared to a $ 5.1 million non - GAAP net income in the third quarter of 2020. Diluted non - GAAP net income per share was $ 0.07 in the